Future perspectives in target-specific immunotherapies of myasthenia gravis - Wikidata - awgldk - TriplyDB

Future perspectives in target-specific immunotherapies of myasthenia gravis

Future perspectives in target-specific immunotherapies of myasthenia gravis

http://www.wikidata.org/entity/Q26776225

about

Precision medicine in myasthenia graves: begin from the data precision Mechanisms of Autoantibody-Induced Pathology.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.Pain in autoimmune disorders.Anti-Musk Positive Myasthenia Gravis and Three Semiological Cardinal Signs.Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.Zelldepletion und Myeloablation bei neuroimmunologischen Erkrankungen CIDP, myasthenia gravis, and membranous glomerulonephritis - three autoimmune disorders in one patient: a case report

P2860

Q26748943-889B0A40-053A-4B07-A868-811446CF1A09 Q33740580-3CF831E2-07B8-47F3-B8AC-2B4BAC4214C5 Q36094658-59696D71-C866-4545-87B8-D46EA28A4BB4 Q36237632-7E7523F4-8681-4002-A70E-EAC2C6E6C11E Q38905689-F21EF262-B298-4FA2-AEB2-73BB71CD0DE9 Q41230826-11051D96-4962-4CC5-981A-C4BB5A757160 Q41657907-096A0A80-4A46-4635-B73B-A5DD565DE2D0 Q43077236-6641509A-9148-4CCF-AD8E-1A7092CE48A9 Q49280339-DE529772-6E15-40D6-8CE5-29F5413B4AFC Q57912843-70A63888-41E3-4339-A4EB-9DD72AC338DC Q58782552-929343D8-0C17-4602-ABBE-2EA993288F45

P2860

Future perspectives in target-specific immunotherapies of myasthenia gravis

http://www.wikidata.org/entity/Q26776225

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Future perspectives in target-specific immunotherapies of myasthenia gravis

@ast

Future perspectives in target-specific immunotherapies of myasthenia gravis

@en

Future perspectives in target-specific immunotherapies of myasthenia gravis

@nl

type

label

Future perspectives in target-specific immunotherapies of myasthenia gravis

@ast

Future perspectives in target-specific immunotherapies of myasthenia gravis

@en

Future perspectives in target-specific immunotherapies of myasthenia gravis

@nl

prefLabel

Future perspectives in target-specific immunotherapies of myasthenia gravis

@ast

Future perspectives in target-specific immunotherapies of myasthenia gravis

@en

Future perspectives in target-specific immunotherapies of myasthenia gravis

@nl

P1433

Q26776225-6ACD1D7B-F9C5-415A-A5C4-2A05500AD0E4

P1476

Q26776225-2B8F7202-B5FD-46A3-9BCF-EF1ABBEBE9E0

P2093

Q26776225-B04EAF4B-2205-4079-B80C-7103F07F158F

P2860

Q26776225-07F6100C-B49A-4E10-A23E-632BDD4989E7

Q26776225-1F23A1C9-EE50-4C68-A969-25C1E2989017

Q26776225-20264775-2A5A-4D69-A14C-93F5DCFCBA45

Q26776225-2241920B-8198-486D-AAF0-0386A52E9620

Q26776225-2B7F7B59-51FE-48C3-959A-E2EE34788552

Q26776225-34BB421E-9E8E-4851-A420-613C2C77932A

Q26776225-39CF7002-C991-4C36-9CC1-8F2C9B8B3D56

Q26776225-3B19FEDC-0469-4BFF-83A9-687D4A51D0FA

Q26776225-3D8BC8FC-0D39-4908-865C-1B59DBEDE386

Q26776225-3DF98AC3-E04A-4A1D-9237-EA626301FD0E

P304

Q26776225-098D0152-D3AE-45B2-897E-7F800C02C05D

P31

Q26776225-4B8B3FF3-CF79-4FE6-AB7A-DFD966309277

P3181

Q26776225-CDB5B501-72FD-4925-A626-E011CC839F53

P356

Q26776225-B389102D-E176-4B6E-B643-24616F1DC2F5

P407

Q26776225-DC94F73E-CF06-4858-AC91-ED5DEA334C95

P433

Q26776225-1182A067-B667-4AC1-B35B-4C23FB741BC3

P478

Q26776225-9D3C4943-970D-40BA-B7F5-0C67E9E6F529

P577

Q26776225-600E7C7F-7005-4EF8-9E6E-2A5DD797FFFE

P698

Q26776225-1116233E-46B1-48E2-A62D-CE0A4607AEB5

P921

Q26776225-2E8C14A0-4A92-4A68-8A80-9E23ED5B0F35

Q26776225-449E17AA-C5BF-41D6-BCFE-6DA0430E62BC

P932

Q26776225-C55D4DAE-8BAC-473A-81FF-A28AB522B371

P3181

P356

1756285615605700

P1433

Therapeutic advances in neurological disorders

P1476

Future perspectives in target-specific immunotherapies of myasthenia gravis

@en

P2093

Marinos C Dalakas

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in rheumatology: new targeted therapeutics

Intravenous immunoglobulin for myasthenia gravis

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

Current and emerging therapies in multiple sclerosis: a systematic review

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Signal transduction in T lymphocytes.

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

P304

316-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4134120

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1756285615605700

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26600875

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

4643871

http://www.w3.org/2001/XMLSchema#string